# First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

> **NCT06840782** · PHASE3 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 124 (estimated)

## Conditions studied

- Oligometastatic Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **RADIATION:** Radical local treatment
- **DRUG:** SoC-based immunotherapy (+/- chemotherapy)

## Key facts

- **NCT ID:** NCT06840782
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2030-02
- **Final completion:** 2030-02
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840782, "First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06840782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*